In the present study, we generated a stTRAIL-expressing oncolytic adenovirus replicating under the control of a hypoxia-responsive and cancer-specific H5CmTERT promoter (H5CmTERT-Ad/TRAIL) to achieve robust and selective cancer cell-killing effect for the treatment of glioblastoma. Here, TNFSF10 is linked to glioblastoma.